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Report from the field

Overview of the Sixth Annual Vaccine Renaissance
Conference
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Institute for Immunology and Informatics; University of Rhode Island; Providence, RI USA; 2EpiVax, Inc.; Providence, RI USA
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The Sixth Annual Vaccine Renaissance Conference, hosted by the Institute for Immunology and Informatics (iCubed)
at the University of Rhode Island (URI), took place on October 15–17, 2012. This conference provides a forum for the
review of current progress in the discovery and development of vaccines, and creates an environment for the exchange
of ideas. Dr Joel McCleary opened the conference with a warning about the importance of preparing for well-defined
biowarfare threats, including tularemia and Staphylococcal enterotoxin B. Following the keynote address, sessions
explored biodefense and preparation for pandemic and biowarfare threats; vaccines for emerging and re-emerging
neglected tropical diseases; animal vaccines and human health; and vaccine vectors and the human microbiome. In this
issue of Human Vaccines and Immunotherapeutics, seven Vaccine Renaissance Conference speakers will showcase their
work; here, we describe a few of the conference highlights.

The sixth annual Vaccine Renaissance Conference, hosted
by the Institute for Immunology and Informatics (iCubed)
at the University of Rhode Island, was held in Providence, RI
on October 15–17, 2012. This conference provides a forum for
the review of current progress in vaccine discovery and development, and creates an environment for the exchange of ideas.
In this issue of Human Vaccines & Immunotherapeutics (HV&I),
seven Vaccine Renaissance Conference speakers will showcase
their work; below, we describe a few of the conference highlights. The first session, “Developments in Homeland Security:
From Microbe Hunters to Vaccines on Demand,” started the
conference with a warning from an expert in the field about the
importance of preparing for well-defined biowarfare threats. Joel
McCleary, the chairman and co-founder of Q Global, founder of
PharmAthene, Inc., and former aide to President Jimmy Carter,
presented a historical overview of the US bioweapons program
and summarized his take on current bio-threats,1 which include
tularemia and Staphylococcal enterotoxin B.2 McCleary stated that
the US should plan to have enough of these vaccines stockpiled
for the entire country and reminded the audience that there is no
tularemia vaccine at present. He also emphasized that a bioterror attack would overwhelm victims’ immune systems due to the
high dose of pathogen, and consequently, traditional small molecule drugs like antibiotics would be ineffective for those near the
epicenter of an attack.
Following on the topic of biodefense, Dr Daniel Wolfe and
colleagues from the Joint Science and Technology Office of the

Defense Threat Reduction Agency (DTRA) addressed the need
for a tularemia vaccine highlighted by McCleary. In the current
issue of HV&I, Wolfe et al. identified a lead candidate (Lm-IgIC)
that protects F344 rats against an aerosol challenge of F. tularensis and established a non-human primate model for aerosolized F.
tularensis Type A.3 DTRA has also submitted an Investigational
New Drug (IND) application for a Phase I clinical trial to test
a Venezuelan Equine Encephalitis Virus (VEEV) DNA vaccine.
A ricin vaccine, RVEc, is under development as well; acceptable
safety and immunogenicity have been demonstrated in nonhuman primates, and Phase I clinical trials for RVEc began in
May 2011.
Despite important advances in the strategic preparedness of
the US agencies for biowarfare preparedness, delays in vaccine
design, development, and manufacture remain significant obstacles to effective national biodefense. This is particularly true for
the very real threat of novel pathogens and emerging influenza
pandemic strains. Conventional approaches to vaccine development and production are incompatible with the prompt deployment needed for an effective public health response. One potential
solution to the problem is developing vaccines on demand, as
elucidated by Dr Mark Poznansky, Director of the Vaccine and
Immunotherapy Center at the Massachusetts General Hospital.
Poznansky provided an overview of the DARPA-funded program
for rapid vaccine production that was established in 2011 and
executed in 2012; the VaxCelerate Consortium features local biotech company EpiVax, Inc. as one of its members.
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viral infection. These findings have important implications for
future development of vaccines and therapeutics. Correlates of
protection were also explored by Dr Sharone Green (University
of Massachusetts Medical School), who described how the
mechanisms behind heterologous secondary infections could be
exploited for rational vaccine design.8 Green et al. demonstrated
protection against secondary heterologous Japanese encephalitis
virus infection in a murine model following primary infection
with West Nile virus. These results have broad implications for
neglected tropical disease vaccine development, as cross-conserved epitopes could be selected to create broadly protective
flavivirus vaccines.
The health of animals has a significant bearing on the health
of humans (infectious diseases in particular), and this served as
the impetus behind the “Animal Vaccines and Human Health”
session. Dr Jennifer Steele and her colleagues at Tufts University
Cummings School of Veterinary Medicine reported how hyperimmune bovine colostrum (HBC) harvested from cows vaccinated
during gestation can be used to treat gastrointestinal infections
in humans. HBC, which is rich in targeted immunoglobulins,
has demonstrated efficacy in treating or preventing numerous
diseases, including Clostridium difficile infection (CDI). Steele et
al. inoculated cows with a novel recombinant vaccine containing
the two most important virulence factors of C. difficile, TcdA and
TcdB, and demonstrated in preliminary results that this HBC
product successfully treated CDI in the gnotobiotic piglet model.
Steele notes in the current issue of HV&I that HBC could be
utilized as a valuable alternative to traditional antibiotic treatment, which would have the added benefit of lowering the risks of
damage to the gut microflora, disease recurrence, and antibiotic
resistance.9
Animal vaccination can additionally be applied to the problem of Lyme disease, as demonstrated by Dr Samuel Telford
(Tufts University Cummings School of Veterinary Medicine).
Telford argued that “vector control” such as mass vaccination
of local mouse populations could be implemented concurrently
with a revival of the Lymerix vaccine to halt the spread of Lyme
disease.10 Although the Lymerix vaccine demonstrated 50–70%
efficacy in a Phase II clinical trial, Smith Kline Beecham withdrew the product due to pressure from advocacy groups and poor
sales. In a review of Lyme disease pathology and the history of
Lymerix, Telford found no peer-reviewed evidence of arthritis as
a side effect, even 10 years post vaccination. Telford believes that
Lymerix is both safe and effective in preventing Lyme disease,
which would be of great interest to those who reside in, or visit,
rural areas.
Dr Peter Burkhard, Associate Professor at the University of
Connecticut and CEO of Alpha-O Peptides AG, rounded out
this session with a presentation of his work to develop a protein
nanoparticle vaccine against rodent malaria. The P4c-Mal vaccine tested by Burkhard et al. conferred long-lasting immunity
against Plasmodium berghei sporozoite challenge in BALB/c and
C57Bl/6 mice,12 while a prototype P. falciparum human-indicated vaccine demonstrated protection against lethal challenge in
Wild Type and MHC I knockout C57Bl/6 mice.13 As Burkhard
noted, this vaccine platform has a wide range of applications
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Dr Anne De Groot continued this discussion by detailing
progress on “FastVax,” a program to produce vaccines on demand
for biodefense. De Groot outlined the feasibility of producing a
vaccine for a novel biowarfare agent within 60 days, which would
be 2-fold faster than the rate at which the most recent pandemic
influenza vaccine was produced. The rapid, nimble vaccine design
tools and production technologies currently in use at iCubed and
EpiVax can significantly accelerate vaccine development while
enhancing national security against emerging pathogens and biowarfare agents. In her article in an upcoming issue of HV&I, De
Groot will report on an innovative and distributed solution to
the need for rapid vaccine production capability, and suggests
this approach might be highly relevant to the development of a
vaccine for emerging H7N9 influenza.4
The focus of the conference then shifted from vaccines for
bioterror applications to vaccines for emerging and re-emerging
tropical diseases in the session entitled, “Neglected Tropical
Diseases.” Dr Stephen Thomas, director of the Viral Diseases
Branch at the Walter Reed Army Institute of Research, described
the high social, financial, and healthcare resource costs caused by
the millions of dengue virus infections each year. He stressed that
a safe, efficacious, and widely used dengue vaccine in conjunction with strategic vector control is necessary to reduce the global
dengue burden. As no correlates of protection or validated animal
model of dengue disease have yet been defined, Thomas advocated for continued exploration of the dengue human infection
model with partially attenuated dengue viruses to advance dengue vaccine development. In the current issue of HV&I,5 Thomas
describes the potential application of this human infection model
to the development of new vaccines and therapeutics.
Also in the neglected tropical diseases session, Dr Jonathan
Kurtis (Warren Alpert Medical School of Brown University)
detailed his exciting progress toward a vaccine candidate for
pediatric Plasmodium falciparum malaria. Kurtis et al. demonstrated the protein PfSEP-1, which is involved in schizont egress,
protected from lethal parasite challenge in a mouse model.6 On a
related note, Dr Steven Williams, Gates Professor of Biology and
Biochemistry at Smith College, gave an overview of neglected
tropical diseases and advocated for breaking the cycle of disease
and poverty to improve the economies of developing world countries. Williams, who has long worked in the areas of elephantiasis and African river blindness, noted that despite 40 years of
research, there are still no parasite vaccines available.
While not a neglected tropical disease, hepatitis C virus
(HCV) is a considerable contributor to the global burden of disease, affecting an estimated 180 million people worldwide and
causing a large proportion of chronic liver disease. Dr Phyllis
Losikoff (Department of Medicine, Rhode Island Hospital and
the Warren Alpert Medical School of Brown University) presented the problem of chronically HCV-infected individuals
who are unable to maintain the broad CD4 + and CD8 + T cell
responses required to resolve primary HCV infection. Losikoff
et al. provide evidence in the current issue of HV&I7 demonstrating the role of T regulatory (Treg) cells in the pathogenesis of chronic hepatitis C, as increased Treg populations in
the tissues of HCV-infected patients correlated with persistent
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year, the organizers award a conference scholarship to a student
studying immunology or bioinformatics. This year’s recipient
was Alicia Francis, a student of Jamaican heritage studying bioinformatics at Washington Adventist University in Maryland.
Francis aspires to become a pediatrician and plans to apply her
bioinformatics training to the improvement of women’s and children’s health. Furthermore, the annual “Polly Matzinger Fearless
Scientist Award” recognizes women who entered scientific careers
later in life or who returned to scientific careers after taking time
off. This award, named for NIH scientist and thought leader in
the field of immunology Dr Polly Matzinger, was presented to
Dr Carey Medin, Assistant Research Professor at iCubed. Medin
took time off from her research pursuits to raise her young family but has since returned to academia; in her current position at
iCubed in the laboratory of Dr Alan Rothman, she is analyzing
the pathogenesis of dengue virus.
In conclusion, the Vaccine Renaissance Conference continues
to provide an important forum for discussions of cutting-edge
vaccine research to address unmet public health and biodefense
needs. The small size of the conference creates ample opportunity
for dialog, and a number of important scientific collaborations
have resulted from encounters between researchers at this annual
event.
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that could be expanded through the inclusion of small molecule
attachments (e.g., nicotine vaccine) or full-length protein attachments (e.g., norovirus vaccine).
Vaccine platform design was further explored in the last session, “Vaccine Vectors and Human Microbiome.” In his presentation, Dr James Galen (Center for Vaccine Development at
the University of Maryland School of Medicine) laid out a new
strategy for the development of bacterial live vector vaccines. By
integrating antigen-encoding gene cassettes into multiple chromosomal sites within an attenuated Salmonella enteric serovar
Typhi vaccine candidate, immunogenic chromosomally encoded
antigens can be delivered without sacrificing loss of gene dosage
or further attenuating the vaccine strain. Galen et al. demonstrated the effect of integration site on expression levels of the
green fluorescent protein (GFPuv), and notably observed that
GFPuv expression increased in a growth phase-dependent manner. As Galen points out in the current issue of HV&I,14 this
novel platform expression technology holds high potential for
facilitating development of multivalent live vector vaccines.
The final day of the conference was devoted to hands-on
immunoinformatics and immunology training. This yearly event
trains researchers to use the suite of immunoinformatics tools
developed at EpiVax, Inc. and iCubed. Computational and labbased training provides opportunities for researchers to learn
directly from the informatics and immunology experts in order
to enhance their own research programs. This training session
also provides an opportunity for researchers to network and
establish collaborations.
A valuable role of the Vaccine Renaissance Conference is to
support women and students from diverse and underrepresented
backgrounds who are embarking on scientific careers. Each

